Skip to content

DBV Technologies DBVT Current ratio

Current ratio at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
8.9×-12.7×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10.2×+7.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
10.8×+2.3×
Alumis Inc. logo
Alumis Inc.ALMS
7.5×+3.8×

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×

Where this comes from

Calculated from DBV Technologies’s reported figures.

Based on the most recent quarter.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's current ratio?
DBV Technologies (DBVT) reported current ratio of 4.8× in Q1 2026.
How has DBV Technologies's current ratio changed year-over-year?
DBV Technologies's current ratio increased by 559.8% year-over-year, from 0.7× to 4.8×.
What is the long-term trend for DBV Technologies's current ratio?
Over 5 years (2020 to 2025), DBV Technologies's current ratio has grown at a -1.4% compound annual growth rate (CAGR), from 3.9× to 3.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.